Valeant reported it lost $1.12 per share in the first quarter on revenue of $2.76 billion. Wall Street analysts were expecting the company to earn $1.38 per share on revenue of $2.72 billion.
On March 15, 2016, Valeant issued preliminary unaudited fourth quarter results for 2015, including unaudited revenue of $2.8 billion and GAAP EPS of ($0.98). As stated at that time, those results were preliminary and unaudited. As a result of ongoing analysis and review, and finalization of the results for the fourth quarter of 2015 by the Company, the Company has made adjustments to revenue, GAAP EPS and Adjusted EPS (non-GAAP), resulting in revenue of $2.8 billion, GAAP EPS of ($1.12) and Adjusted EPS (non-GAAP) of $1.55. The majority of the impact is attributed to adjustments relating to the deferral of Addyi® revenue, adjustments to the returns reserve of Xifaxan®, as well as several items, including increased professional service fees and intellectual property related adjustments, post March 15, 2016
so passt es in Bild der Erwartungen statt der 10-11 sind 8 -9 Mrd geworden
trifft es bei mir ganz gut. Offenbar waren meine Erwartungen deutlich zu hoch. Das Plus ist ja komplett weg und das Volumen ist sehr, sehr gering, wenn man den ersten 5 Minuten absieht.
die Bewertung ist auch bei Skepsis deutlich zu niedrig. Das ist keine Pennystock, da wollen Funds rein. Nur der Kurs ist eindeutig entäuschend, noch........